Add to watchlist:

Only registered members can add into watchlist !

Register here !
Deal NanoViricides Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.


NanoViricides submits orphan drug application for DengueCide in Europe

The application was submitted to the European Medicines Agency on behalf of the company by the European associates of consulting firm Cote Orphan Consulting. The drug candidate already has orphan status in the U.S., which the company announced last month.

NanoViricides (OTCBB:NNVC) says that its orphan drug application in Europe for its DengueCide candidate has been submitted, putting the company one step closer to developing a drug to treat the mosquito-borne dengue virus. 

The application was submitted to the European Medicines Agency on behalf of the company by the European associates of consulting firm Cote Orphan Consulting. The drug candidate already has orphan status in the U.S., which the company announced last month. 

DengueCide, which is in pre-clinical development stage, still has to go through the human trial stage.NanoViricides,  which has six commercially important drug candidates in its pipeline that together address a market size of greater than $40 billion, says DengueCide has shown "very high effectiveness" in animal studies, in the U.S. 

Indeed, in the mouse study conducted at the University of California, those mice treated with DengueCide achieved a 50 per cent survival rate, as opposed to a 100 per cent fatality rate when left untreated. There is currently no drug treatment or vaccine for the dengue virus, with the orphan drug status expected to help the company give DengueCide a higher priority and move it forward rapidly following the development of its own flu treatment, FluCide.

Dengue fever is an old disease that has re-emerged in the past 20 years, with an estimated 400 million cases of the tropical infectious disease in 2013 and between 50,000 to 100,000 deaths annually. 

The company said in its statement Tuesday that interest in the disease in Europe was confirmed by the announcement last week that Johnson & Johnson has signed a collaboration with the Wellcome Trust and the University of Leuven in Belgium  to develop antiviral drugs for the dengue infection.

According to the NanoViricides release, 13 European countries have reported 82 imported dengue cases, including a major outbreak on the Portuguese island of Madeira. 

Aside from DengueCide, the drug development company is first focused on bringing its FluCide treatment to market. It currently has both an oral and injectable version of FluCide, which has the potential to wipe out virtually all strains of the pesky influenza A virus. The company is now preparing for toxicology studies for its first FluCide candidate, expected to be wrapped up before the middle of next year. 

So far in 2013, NanoViricides' stock has surged over 160 per cent, closing Friday at $1.21. 

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.